In addition to upregulation of CTLA-4 and PD-1 on tumor-infiltrated T cells, in many tumors, the CD28 ligands CD80 and CD86 are poorly expressed both on tumor cells and tumor-associated myeloid cells11–13,45. Here, CD80 is linked to neoplasm.